Nigam et al. 33 recently demonstrated the potential for non-invasive quantification of tumor-infiltrating CD11b+ immune cells in a mouse model of glioma using PET with 89Zr-deferoxamine chelated anti-CD11b of the same clone (clone M1/70). This evidence concerns the gene ITGAM and central nervous system cancer.